Janus Henderson Group PLC Lowers Position in Janux Therapeutics, Inc. $JANX

Janus Henderson Group PLC lessened its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 21.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 4,196,409 shares of the company’s stock after selling 1,154,044 shares during the quarter. Janus Henderson Group PLC owned approximately 0.07% of Janux Therapeutics worth $58,280,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in JANX. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Janux Therapeutics in the 4th quarter valued at about $34,000. Caitong International Asset Management Co. Ltd acquired a new stake in Janux Therapeutics during the 4th quarter worth about $51,000. Osaic Holdings Inc. boosted its position in Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after buying an additional 3,037 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in Janux Therapeutics in the fourth quarter valued at $137,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 2.6%

JANX opened at $15.17 on Friday. The business has a fifty day simple moving average of $14.91 and a 200-day simple moving average of $14.38. Janux Therapeutics, Inc. has a 52 week low of $12.12 and a 52 week high of $35.34. The firm has a market cap of $925.07 million, a P/E ratio of -8.24 and a beta of 2.52.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million. Sell-side analysts expect that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on JANX shares. Piper Sandler lowered their price objective on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. UBS Group cut Janux Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $57.00 to $15.00 in a report on Wednesday, April 15th. Evercore set a $22.00 target price on shares of Janux Therapeutics in a research note on Monday, May 11th. Truist Financial restated a “buy” rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Finally, Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.08.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, VP Maria Dobek sold 2,038 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $14.17, for a total transaction of $28,878.46. Following the completion of the transaction, the vice president owned 32,270 shares in the company, valued at $457,265.90. The trade was a 5.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Janeen Noel Doyle sold 4,059 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the transaction, the insider owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 7.90% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.